This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clinical efficacy of infliximab

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A number of double blind, placebo-controlled studies have shown the efficacy of infliximab in rheumatoid arthritis.

In a study of 73 patients on infliximab alone (i.e. without concomitant methotrexate) a Paulus 20% response occurred in 79% on a dose of 10mg/kg, 44% on 1mg/kg and 8% on placebo.

In a 26 week study of 101 patients, Paulus 20% responses lasted longer with infliximab (1-10mg/kg) plus methotrexate (7.5mg/wk) - (>16.5 weeks) and infliximab (3mg/kg or 10mg/kg) plus placebo (10.4-17.2 wks) than with control therapy (0 weeks).

In a study of 428 patients on methotrexate and either infliximab or placebo over 54 weeks, ACR20 responses were obtained as follows: 3mg/kg every 4 weeks - 48%, 3mg/kg every 8 weeks - 42%, 10mg/kg every 4 weeks 59%, 10mg/kg every 8 weeks 59%, placebo 17%. Progression of radiographic erosions improved in those on infliximab and methotrexate.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.